Home › Research › Biomarkers
Blood Biomarkers of Alzheimer’s Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial
Rosenberg A, Solomon A, Matton A, Lehtisalo J, Benedet AL, Mangialasche F, Levälahti E, Arslan B et al.. medRxiv, 2026-10-06
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
Interventions targeting lifestyle and health behaviors support cognition in older adults at risk of dementia. It remains unclear if the cognitive benefit of such interventions is modified by Alzheimer’s disease (AD)-related neuropathology, and if lifestyle interventions lead to changes in blood AD biomarkers. Here, we analyzed core AD plasma biomarkers (Aβ, p-tau181, p-tau217, p-tau231, NFL, GFAP) in the two-year FINGER randomized controlled multidomain lifestyle trial, which demonstrated cognitive efficacy in an at-risk older general population (N=1260). We found that 85% of participants had p-tau217 below the pathological threshold at baseline (Lumipulse assay). Higher biomarker levels were associated with less favorable cognitive trajectories over two years, but their ability to predict brain amyloid accumulation on PET scans was modest (e.g., p-tau217 AUC 0.72). We found no indication that baseline biomarker levels significantly modified the cognitive benefits of the intervention. Changes in biomarkers were small over two years, with most participants (82%) remaining below the pathological p-tau217 threshold. Biomarker trajectories were similar in the intervention and control groups, suggesting that the cognitive benefits of the two-year lifestyle intervention in at-risk individuals without substantial impairment may primarily involve mechanistic pathways not captured by AD blood biomarkers. These findings provide new evidence to clarify the role of AD blood biomarkers for risk stratification and prediction of response to lifestyle interventions, which is crucial to inform future dementia precision prevention strategies. ClinicalTrials.gov ID NCT01041989 .
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rosenberg, A., Solomon, A., Matton, A., Lehtisalo, J., Benedet, A. L., Mangialasche, F., et al. (2026). Blood Biomarkers of Alzheimer’s Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial. medRxiv. https://doi.org/10.64898/2026.10.02.26364486
Vancouver
Rosenberg A, Solomon A, Matton A, Lehtisalo J, Benedet AL, Mangialasche F, et al. Blood Biomarkers of Alzheimer’s Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial. medRxiv. 2026. doi:10.64898/2026.10.02.26364486.
BibTeX
@article{rosenberg2026-f728d2cc,
author = {Rosenberg, A. and Solomon, A. and Matton, A. and Lehtisalo, J. and Benedet, A. L. and Mangialasche, F. and Levälahti, E. and Arslan, B. and others},
title = {{Blood Biomarkers of Alzheimer’s Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.10.02.26364486},
url = {https://doi.org/10.64898/2026.10.02.26364486}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Here, we analyzed core AD plasma biomarkers (Aβ, p-tau181, p-tau217, p-tau231, NFL, GFAP) in the two-year FINGER randomized controlled multidomain lifestyle trial, which demonstrated cognitive efficacy in an at-risk older general population (N=1260).
- We found that 85% of participants had p-tau217 below the pathological threshold at baseline (Lumipulse assay).
- Higher biomarker levels were associated with less favorable cognitive trajectories over two years, but their ability to predict brain amyloid accumulation on PET scans was modest (e.g., p-tau217 AUC 0.72).
- We found no indication that baseline biomarker levels significantly modified the cognitive benefits of the intervention.
- Biomarker trajectories were similar in the intervention and control groups, suggesting that the cognitive benefits of the two-year lifestyle intervention in at-risk individuals without substantial impairment may primarily involve mechanistic pathways not captured by AD blood biomarkers.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants1,260
- Effect sizeAUC 0.72
- Evidence strengthHigh
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 44 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for study design because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 27 of the 62 points we could judge it on, which is 44 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,260 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 27 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 27 of the 62 points we could judge it on is 44 out of 100. |
| Total | 44 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.